Tenaya Therapeutics (TNYA) Operating Expenses (2020 - 2026)

Tenaya Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $20.3 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 26.32% year-over-year to $20.3 million; the TTM figure through Mar 2026 stood at $86.1 million (down 21.55% YoY), while the FY2025 annual figure was $93.3 million, down 19.51% from the prior year.
• Operating Expenses was $20.3 million for Q1 2026 at Tenaya Therapeutics, down from $20.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $35.1 million in Q2 2023 to a low of $20.3 million in Q1 2026.
• Historically, Operating Expenses has averaged $28.6 million across 5 years, with a median of $30.8 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses surged 137.73% in 2022, then dropped 26.32% in 2026.
• A 5-year view of Operating Expenses shows it stood at $34.6 million in 2022, then retreated by 8.98% to $31.4 million in 2023, then slipped by 21.61% to $24.7 million in 2024, then decreased by 15.73% to $20.8 million in 2025, then slipped by 2.33% to $20.3 million in 2026.
• The last three Operating Expenses figures came in at $20.3 million (Q1 2026), $20.8 million (Q4 2025), and $20.9 million (Q3 2025), per Business Quant data.